This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEA601E0_M.jpg
The Zacks Consensus Estimates predict growth for HCA’s upcoming earnings report due on October 24, 2023. The forecast includes earnings per share (EPS) of $3.97 and revenue of $15.78 billion. This aligns with InvestingPro Tips which indicate that HCA’s strong earnings should allow management to continue dividend payments and that the company has been profitable over the last twelve months.
The company holds a Zacks Rank of #3 (Hold), which is part of a system that often sees top-rated stocks yield high returns. This rank, combined with the recent upward shift of 0.06% in the Zacks Consensus EPS estimate for HCA, signals positive expectations for the company’s performance in upcoming trading sessions.
In terms of valuation, HCA’s Forward Price-to-Earnings (P/E) ratio exceeds its industry average, suggesting it is trading at a premium. According to InvestingPro data, the company’s P/E Ratio stands at 11.83. However, its lower Price/Earnings to Growth (PEG) ratio indicates good value relative to its expected growth rate. The company’s PEG Ratio as of LTM2023.Q2 is -4.02, which further emphasizes this point.
HCA is part of the Medical – Hospital industry within the Medical sector, which ranks in the top 26% of all industries according to Zacks. Historically, industries in the top half have been known to outperform those in the bottom half by a factor of 2 to 1, suggesting potential for continued performance from HCA Healthcare. As per InvestingPro Tips, HCA is a prominent player in the Healthcare Providers and services industry, and it operates with a high return on assets, which was 13.21% as of LTM2023.Q2.
For more insights like these, investors can explore the InvestingPro product which includes additional tips and real-time metrics, available at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
